Gencor’s Levagen+ supports exercise performance, study finds

Published: 27-Jun-2024

The study determined that Levagen+ can positively impact exercise performance whilst not interfering with muscle hypertrophy

Gencor, a botanical ingredients provider for the nutraceutical industry, has published a human clinical study indicating that Levagen+, its palmitoylethanolamide (PEA) ingredient, can enhance lower body power in healthy, active individuals.

Over the counter medications have previously been shown to negatively affect skeletal muscle adaptation to strength training, which can be a significant issue in those who consume them.

Therefore, Gencor wanted to determine if Levagen+ could impact exercise performance in a way that doesn’t interfere with skeletal muscle hypertrophy. 


The study

During the randomised, double-blind study, healthy and active participants were divided into two groups — one of which received 350mg of Levagen+ and one who received a placebo. 

The trial ran for eight weeks, and participants were instructed to conduct resistance training within this period. 


A 350mg dose of Levagen+ improves lower body power and isometric strength by 12%


The results

During the eight week period, it was proven that a daily 350mg dose of Levagen+ was able to significantly improve lower body power and isometric strength by 12%.

It also revealed that PEA supplementation didn’t inhibit strength training adaptations. 

“To our knowledge, this is the first study to investigate the effects of PEA on the adaptive responses to strength training.” said Co-Founder and Managing Director at Gencor, R.V. Venkatesh. “This is our second study investigating Levagen+ for active nutrition, and it continues to show great promise in this category.”

Relevant companies

You may also like